The memory reflects that last year's board approved the pre-delivery of a remuneration of 12.5 million, compared to 5.1 million the previous year.
IVI-RMA, the company that resulted from the merger between the Valencian Infertility Institute (IVI) and the American RMA six years ago, has just changed hands, and in March it announced that its new majority shareholder is the investment fund